Saturday, January 27, 2018

COLON SESSION

Quality Measures in Colonoscopy: How to Achieve Them and Why?
Aasma Shaukat, MD, MPH, FACG, FASGE
Describe current colonoscopy quality measures and why they are important in the GI practice.

Failed Colonoscopy: What Next?
Steven A. Edmundowicz, MD, FASGE
Discuss various approaches and options when traditional colonoscopy fails.

The Difficult Colon Polyp: Tricks and Options for Resection
Shivangi T. Kothari, MD, FACG, FASGE
Identify management and resection techniques for difficult colon polyps.

Update in the Treatment of C. difficile Infection
Colleen R. Kelly, MD, FACG
Summarize treatment options for C. difficile including FMT.

HEPATOLOGY SESSION

Autoimmune Hepatitis: Diagnosis and Management
Mitchell L. Shiffman, MD, FACG
Outline diagnosis and treatment options for autoimmune hepatitis.

Managing the Patient with Decompensated Cirrhosis
Tram T. Tran, MD, FACG
Explain the approach to managing a patient with decompensated cirrhosis and its complications.

Up-to-Date Treatment of Hepatitis C
Paul Y. Kwo, MD, FACG
Recognize current treatments for chronic hepatitis C.

ESOPHAGUS SESSION

The Refractory Benign Esophageal Stricture (RBES): What to Do?
Karen L. Woods, MD, FACG, FASGE
Define endoscopic and surgical approaches to patients with RBES and discuss treatment algorithms.

Esophageal Motility Disorders: What You Need to Know
John E. Pandolfino, MD, MSCI, FACG
Discuss esophageal motility disorders and the role of manometry in their diagnosis and management.

Barrett’s Esophagus: Diagnosis, Treatment, and Surveillance
Nicholas J. Shaheen, MD, MPH, FACG, FASGE
Apply current management of Barrett’s esophagus, emphasizing eradication techniques, including risks and benefits.

Eosinophilic Esophagitis (EoE): Beyond PPI Therapy
Kenneth R. DeVault, MD, FACG
Propose therapeutic options for patients with EoE who fail first-line therapy.
PRACTICE MANAGEMENT SESSION

Working Luncheon Presentation: Telemedicine Opportunities for the GI Practice
Raymond K. Cross, Jr. MD, MS
Identify opportunities to utilize telemedicine in a GI practice.

Incorporating Non-Physician Clinicians into Your Practice
Daniel J. Pambianco, MD, FACP, FASGE
Explain how to successfully incorporate non-physician clinicians into a practice setting.

Merit-based Incentive Payment System (MIPS) in 2018
Costas H. Kefalas, MD, MMM, FACP, FASGE
List the requirements for MIPS in 2018.

AFTERNOON BREAKOUT SESSION

Stump the Chumps!
Case Presenter: Douglas G. Adler, MD, FACP, FASGE
Panel Members: John R. Saltzman, MD, FACP, FASGE, and David A. Greenwald, MD, FACP, FASGE
Compare diagnostic and treatment recommendations for a challenging case.

I've Been Sued! Now What?
Douglas G. Adler, MD, FACP, FASGE
Analyze the mechanics of a malpractice lawsuit and discuss strategies to reduce risk and to cope with realities of a lawsuit.

Battling Physician Burnout
Christina M. Surawicz, MD, MACG
Recognize, prevent, and treat burnout among physicians.

Endoscopic Treatments for Obesity: Science Fact or Science Fiction?
Ali A. Siddiqui, MD
Appraise current and proposed endoscopic treatments for obesity.

Sunday, January 28, 2018

STOMACH AND SMALL BOWEL SESSION

Managing the Bloated Patient: Role of Diet, FODMAP, Antibiotics, and Probiotics
William D. Chey, MD, FACP
Discuss causes and management of bloating in irritable bowel syndrome and the role of microbiome.

GI Bleed Management: Tricks of the Trade
John R. Saltzman, MD, FACP, FASGE
Describe an overview and application of various hemostasis techniques.

Dyspepsia in 2018: Evaluation and Management
Brian E. Lacy, MD, PhD, FACP
Compare approach and treatment strategy in the dyspeptic patient.

PANCREATICOBILIARY SESSION

Post-ERCP Pancreatitis (PEP): How to Cause, How to Prevent!
Douglas G. Adler, MD, FACP, FASGE
Identify current knowledge regarding PEP, its prevention, and current controversies.

Cystic Pancreatic Neoplasms: What’s New in 2018?
Jeffrey H. Lee, MD, MPH, FACP, FASGE
Explain the management of cystic pancreatic neoplasms, with an emphasis on new guidelines.
The Difficult Common Bile Duct Stone: What to Do?
Amit Rastogi, MD
Compare strategies to remove large or complex bile duct stones.

Should I Stop Doing ERCP?
Ashley L. Faulx, MD, FACG, FASGE
Describe the nature of modern ERCP practice, quality benchmarks, and reasons to pursue or stop doing these procedures.

IBD SESSION

Management of Ulcerative Colitis: Updated ACG Practice Guidelines
David T. Rubin, MD, FACG
Apply updated ACG practice guidelines for the management of ulcerative colitis.

Review of Biologics for the Treatment of IBD
Jean-Paul Achkar, MD, FACG
Evaluate available biologic agents for treatment of IBD and understand indications for their selection.

The Role of Biosimilars in IBD: Principles and Indications
Stephen B. Hanauer, MD, FACG
Outline basic principles of biosimilars and define indications for their use in treating patients with IBD.

Practical Approach to IBD Therapeutic Drug Monitoring
David A. Schwartz, MD, FACG
Define tests utilized to monitor drug therapy in IBD and explain when to order them.
Friday, March 9, 2018

Chronic PPI Therapy for GERD: Risks, Benefits, and Alternatives
Kenneth R. DeVault, MD, FACG
Identify ongoing concerns regarding the risks of chronic PPI therapy, evidence supporting the use of this therapy, and other options for management of GERD.

Saturday, March 10, 2018

LIVER DISEASE SESSION

Diagnosis and Management of Portal Hypertension: New Recommendations
Fredric G. Regenstein, MD, FACG
Assess recent developments on the topic of portal hypertension and how these developments impact our current understanding and treatment of this disorder.

Evolving Treatment of NASH
Zobair M. Younossi, MD, MPH, FACG
Evaluate current therapy recommendations for NASH as well as novel therapies currently in development which show promise in managing this condition.

Conquering the Hepatitis C Epidemic
Jorge L. Herrera, MD, MACG
Analyze the status of the hepatitis C epidemic, including current treatment options and eradication initiatives.

INFLAMMATORY BOWEL DISEASE SESSION

Recognizing and Treating Extraintestinal Manifestations of IBD
Shabana F. Pasha, MD
Review complications of inflammatory bowel disease found outside of the gastrointestinal tract, as well as treatment options tailored to individual pathologies.

Biologic Therapy in IBD: Beyond Anti-TNF Agents
Kara M. De Felice, MD
Explain the utility of recently introduced and future biologic therapy agents in the IBD treatment algorithm.

State-of-the-Art Surveillance in IBD
Samir A. Shah, MD, FACG
Assess current recommendations and practice standards for colorectal cancer surveillance in IBD populations.

Neurobiology of Stress and IBS
Lin Chang, MD, FACG
Describe interactions between the central nervous system and gastrointestinal tract, including assessing the impact of psychological factors such as stress on symptoms of irritable bowel syndrome.

ENDOSCOPY SESSION

Peri-endoscopic Management of Anti-thrombotics
Daniel L. Raines, MD, FACG
Discuss current guidelines regarding the management of anti-platelet and anti-coagulant agents around the time of endoscopy.

Endoscopic Treatment of Foregut Surgical Complications
John E. Pandolfino, MD, MSCI, FACG
Review complications of surgery involving the upper gastrointestinal tract and the role of endoscopy in their management.
Simple Endoscopic Mucosal Resection
John R. Saltzman, MD, FACG
Identify the indications, risks, and techniques for endoscopic mucosal resection which may be useful to
general gastroenterologists as well as therapeutic endoscopists.

Saturday, March 11, 2018

PRACTICE MANAGEMENT SESSION

Efficiencies in Your Endoscopy Unit
Klaus Mergener, MD, PhD, MBA, FACG
Recognize opportunities to improve endoscopy unit protocols in order to positively impact both patient care
and revenue.

Expected Changes in CMS Reimbursement
Caroll D. Koscheski, MD, FACG
Discuss projected changes in Medicare reimbursement in the U.S., including adjustments in physician, facility,
and anesthesia fees.

Optimizing the Use of Advanced Practitioners
Daniel J. Pambianco, MD, FACG
Identify how advanced practitioners can play a critical role in digestive disease healthcare models in both
academic and private practice settings.

SUPPLEMENTAL PURSUITS SESSION

Developing a Clinical Trials Program
Harry E. Sarles, Jr., MD, FACG
Describe models for initiating and managing an effective clinical trials program which brings value to patients
while providing a financial advantage.

Serving as an Expert Witness
Richard E. Moses, DO, JD, FACG
Recognize the role of gastroenterologists in evaluating legal cases as a supplement to clinical practice,
including discussion of case recruitment, payment rates, skill-set, and pitfalls.

Telemedicine
Raymond K. Cross, Jr., MD, MS
Define how telemedicine can be used to enhance and expand your current practice.
Friday, March 16, 2018

SESSION 1: COLON CANCER SCREENING

Enhanced Endoscopic Techniques to Improve Adenoma and Serrated Polyp Detection
Douglas K. Rex, MD, MACG
Outline enhanced endoscopic techniques including NBI, caps, chromo endoscopy, new scopes, and water immersion, used to improve polyp detection.

Optimal Methods for Colorectal Polypectomy
Michael B. Wallace, MD, MPH, FACG
Describe optimal methods to remove small and large polyps including new guidelines for cold snare polypectomy, review methods to resect large, lateral spreading polyps, including endoscopic mucosal resection (EMR), and discuss methods for removing polyps in difficult locations, such as the IC valve, behind folds, and anal verge.

SESSION 2: THERAPEUTIC ENDOSCOPY

The Role of Endoscopy for Bariatric Patients
Victoria Gomez, MD
Evaluate primary endoscopic therapies for obesity and techniques for the management of post-surgical weight regain, leaks, fistulae, and retained suture material.

Advances in EUS and Pancreatic Disorders
Robert H. Hawes, MD, FACG
Summarize how advances in EUS have improved the management of pancreatic cysts, pancreatic fluid collection, and biliary obstruction.

Advances in Endoscopic Resection, Top to Bottom
Peter V. Draganov, MD, FACG
Discuss EMR, ESD, cap methods, and the closure of perforations.

Saturday, March 17, 2018

SESSION 3: ESOPHAGEAL CONDITIONS

Treatment Endpoints for Eosinophilic Esophagitis
Joel E. Richter, MD, MACG
Recognize the symptoms and histology of eosinophilic esophagitis, and describe the role of allergists and nutritionists in reaching treatment endpoints.

Managing Barrett’s Esophagus After Ablation: Are We Done Now?
Herbert C. Wolfsen, MD, FACG
Apply the most recent guideline recommendations on management of Barrett’s patients after complete elimination of intestinal metaplasia; discuss interval of surveillance, treatment of recurrent metaplasia and/or dysplasia, the goal of antireflux therapy (PPI vs surgery), and chemoprevention (ASA).

GERD: Why, When, and How Do I Stop PPIs?
Joel E. Richter, MD, MACG
Explain the available data regarding side effects from long-term PPI use, and identify management strategies for when and how to stop it.
SESSION 4: FUNCTIONAL GI AND MOTILITY

Doctor, I Have SIBO. Really?
William D. Chey, MD, FACG
Describe the epidemiology, pathogenesis, clinical manifestations, diagnosis, and treatment of SIBO.

Pelvic Floor Dysfunction and Fecal Incontinence: Diagnosis and Therapy
Satish S.C. Rao, MD, PhD, FACG
Identify the various approaches to patients with suspected pelvic floor dysfunction and fecal incontinence, including diagnostic modalities and treatment options, including pelvic floor therapy.

New Options for Medical Management of IBS
William D. Chey, MD, FACG
Discuss new treatment strategies and medications including alternative natural remedies to manage IBS.

Saturday, March 18, 2018

SESSION 5: HEPATOLOGY

Non-invasive Assessment for Liver Fibrosis: Is This the End of Liver Biopsy?
Paul Martin, MD, FACG
Describe non-invasive alternatives to liver biopsy (elastography and chemical markers) for determining the degree of fibrosis in chronic liver disease.

Drug Induced Liver Injury: Review of the New ACG Guideline
Roberto J. Firpi, MD, MS, FACG
Identify evidence-based recommendations for the diagnosis and management of drug induced liver injury (DILI) with emphasis on when to refer patients to transplant centers.

HCV Update: Which Drug Do I Choose for the Treatment Naïve Patient?
Andrew P. Keaveny, MD
Outline the most recently approved medications for treatment of HCV, highlighting the treatment-naïve patient.

SESSION 6: IBD

Tailoring Anti-TNF Dosing Based on Drug and Anti-drug Antibody Level
Jason K. Hou, MD, MS, FACG
Describe clinical strategies tailoring anti-TNF closing based on drug and anti-drug antibody levels.

The Role of Advanced Imaging in IBD Colonoscopy
Michael F. Picco, MD, PhD, FACG
Discuss the role of advanced imaging colonoscopy in the assessment of inflammation, dysplasia detection, and management of IBD.

The Role of Biosimilars in Inflammatory Bowel Disease
Jason K. Hou, MD, MS, FACG
Explain the role, efficacy, and safety of biosimilars in management of IBD patients.
Understanding the Epidemiology and Natural History of IBD for Clinicians
Ashwin N. Ananthakrishnan, MD, MPH
Describe the epidemiology, natural history, and theories regarding the development of IBD, and differentiate IBD from its mimics.

Goals of Caring for the IBD Patient
Corey A. Siegel, MD, MS
Analyze the available data and positioning in IBD management of patient-centered goals and published algorithms of care.

Thoughtful Application of Diagnostic Tools in IBD: When to Use What
Samir A. Shah, MD, FACP
Discuss the appropriateness and timing of various diagnostic tools in IBD and review pearls for their proper use.

How to Think About Immune Suppressive Agents in the Era of Biologics
Francis A. Farraye, MD, MSc, FACP
Explain the roles and positioning of immune suppressive agents including steroids, thiopurines, methotrexate, and tacrolimus.

Biological Therapies in IBD: The Revolution in IBD
David T. Rubin, MD, FACP
Recognize the role of biologics including appropriate candidates, the various mechanisms of action, and data to support each.

Drug and Disease Monitoring
Corey A. Siegel, MD, MS
Critically analyze the available data supporting therapeutic drug monitoring, recommendations for pre-therapy testing, and proactive management while receiving therapies.

Timing of Surgery and Prevention of Post-operative Recurrence
David T. Rubin, MD, FACP
Outline the management of patients who are surgical candidates, and describe the management of patients in the post-operative period.

Cancer Prevention in IBD
Francis A. Farraye, MD, MSc, FACP
Summarize primary and secondary cancer prevention in IBD patients, including the use of chromoendoscopy.

Management of EIM: Disease-related, Disease-unrelated, and Therapy-related
Jean-Paul Achkar, MD, FACP
Identify non-gastrointestinal conditions associated with IBD and their management.

Complementary and Alternative Medicine in IBD
Ali Keshavarzian, MD, MACG
Interpret the evidence base for popular alternative therapies including medical marijuana, herbal remedies, and probiotics.

Diet and Nutrition
Ali Keshavarzian, MD, MACG
Outline the evidence for different diets in managing patients with IBD.

The Pregnant Patient With IBD
Sonia Friedman, MD, FACP
Discuss IBD management strategies before and during pregnancy.

Microscopic Colitis
Ashwin N. Ananthakrishnan, MD, MPH
Describe the epidemiology and management of microscopic colitis.
Saturday, April 14, 2018

SESSION 1: DYSEPSIA AND MORE
Moderator: Paul Moayyedi, MB ChB, PhD, MPH, FACG

Review of the ACG Management of Dyspepsia Guidelines
Paul Moayyedi, MB ChB, PhD, MPH, FACG
Describe the key points of the recently published ACG dyspepsia guidelines.

IBS Pearls and Pitfalls
Brian E. Lacy, MD, PhD, FACG
Discuss practical approaches in the management of IBS patients.

Difficult Functional Cases – The Experts Debate
Moderator: Jeffry L. Nestler, MD, FACG
Panelists: Brian E. Lacy, MD, PhD, FACG, and Paul Moayyedi, MB ChB, PhD, MPH, FACG
Illustrate the management of complicated functional patients in a case-based format.

SESSION 2: PREVENTIVE CARE IN IBD AND MORE
Moderator: Maria T. Abreu, MD

Preventive Care in IBD
Francis A. Farraye, MD, MSc, FACG
Explain the key points of the ACG Prevention in IBD guidelines.

New Agents in Clinical Practice
Maria T. Abreu, MD
Identify the role of biosimilars and drug monitoring in IBD patients.

Difficult IBD Cases – The Experts Debate
Moderator: Timothy B. Gardner, MD, MS, FACG
Panelists: Maria T. Abreu, MD, and Francis A. Farraye, MD, MSc, FACG
Demonstrate the management of complicated IBD patients in a case-based format.

SESSION 3: COLON CANCER SCREENING AND MORE
Moderator: Carol A. Burke, MD, FACG

Review of Current Colorectal Cancer Screening Guidelines
Carol A. Burke, MD, FACG
Summarize the updated ACG colon cancer screening guidelines.

Genetic Testing for Colorectal Cancer
Fay Kastrinos, MD, MPH
Define the important genetic components of colon cancer screening.

Difficult CRC Cases – The Experts Debate
Moderator: Jeffry L. Nestler, MD, FACG
Panelists: Carol A. Burke, MD, FACG, and Fay Kastrinos, MD, MPH
Compare the management of complicated CRC patients.

Bariatric Endoscopy 2018
Christopher C. Thompson, MD, MSc, FACG
Recognize the advances in bariatric endoscopy and their implications for the gastroenterologist.
AFTERNOON BREAKOUT SESSION

Pancreatic Cysts: Much Ado About Nothing
Christopher J. DiMaio, MD, FACG
Define the current management considerations for pancreatic cystic disease.

Barrett’s Esophagus: From Surveillance to Ablation
Nicholas J. Shaheen, MD, MPH, FACG
Discuss the options for management of Barrett’s esophagus.

Complementary and Alternative Medicine Therapies for the Gastroenterologist
Ali Keshavarzian, MD, MACG
Appraise CAM therapies that can be used by gastroenterologists.

Fecal Transplant: *C. difficile* and Beyond
Amy Barto, MD
Outline the current clinical state of fecal transplantation.

Sunday, April 15, 2018

SESSION 4: EVALUATION OF ABNORMAL LIVER TESTS AND MORE
Moderator: Mitchell L. Shiffman, MD, FACG

Review of ACG Guidelines on Evaluation of Abnormal Liver Chemistries
Stanley M. Cohen, MD, FACG
Identify the most important features of the ACG abnormal liver chemistry guidelines.

Hepatitis C Treatment – What Do I Really Need to Know?
Mitchell L. Shiffman, MD, FACG
Describe the up-to-date management of chronic active hepatitis C.

Difficult Hepatology Cases – The Experts Debate
Moderator: Timothy B. Gardner, MD, MS, FACG
Panelists: Stanley M. Cohen, MD, FACG, and Mitchell L. Shiffman, MD, FACG
Explain management of complicated hepatology patients.

SESSION 5: DIAGNOSIS AND MANAGEMENT OF ACHALASIA AND MORE
Moderator: Stavros N. Stavropoulos, MD

High Resolution Manometry: Helpful or Hype?
Philip O. Katz, MD, MACG
Distinguish the benefits of performing high-resolution manometry.

Achalasia: POEM / Dilation / Myotomy
Stavros N. Stavropoulos, MD
Analyze different approaches to the management of achalasia.

Difficult Esophageal Cases – The Experts Debate
Moderator: Jeffry L. Nestler, MD, FACG
Panelists: Philip O. Katz, MD, MACG, and Stavros N. Stavropoulos, MD
Compare the management of esophageal patients.
Saturday, August 25, 2018

SESSION 1: LOWER GI
Moderator: John R. Saltzman, MD, FACG

Acute Lower GI Bleeding: Review of the Newest Management Guidelines
John R. Saltzman, MD, FACG
Describe the various endoscopic modalities for hemostasis, the importance of prep and timing of endoscopy in acute lower GI bleeding, and strategies to prevent recurrent bleeding.

New Developments in Non-Surgical Management of the Patient With Diverticular Disease
Lisa L. Strate, MD, MPH, FACG
Discuss the emerging literature regarding epidemiology and pathophysiology of diverticulitis, and discuss current management strategies for acute and chronic diverticular disease.

New Therapies for IBS: Present and Future
Brooks D. Cash, MD, FACG
Examine the safety and efficacy of current and future pharmacotherapy, and discuss the role of dietary manipulations and psychological interventions in treating patients with IBS.

SESSION 2: IBD
Moderator: Ece A. Mutlu, MD, MS, MBA, FACG

Incorporating New Therapies Into the Care of Your IBD Patient: Where Are We Headed in 2018?
Anita Afzali, MD, MPH, FACG
Identify the available therapies for IBD, their applications in special populations, such as the elderly, pregnant women, patients with a cancer history, and identify new treatments in the pipeline and which IBD patients they would most benefit.

Managing IBD for Optimal Patient Care: Medical Homes, Telemedicine, Apps, and Beyond
Miguel D. Regueiro, MD, FACG
Define goals of optimal treatment in the IBD patient, and review practical issues for quality improvement in IBD care, including setting up a medical home and implementing telemedicine in practice.

Therapeutic Drug Monitoring in the IBD Patient: Reactive or Proactive?
Jeffry A. Katz, MD
Describe the current guidelines on therapeutic drug monitoring, available tests and their interpretations, and discuss the evidence for reactive vs. proactive TDM.

SESSION 3: HEPATOLOGY
Moderator: Jasmohan S. Bajaj, MD, MSc, FACG

Alcoholic Hepatitis: Treatment and Transplant Considerations
Jasmohan S. Bajaj, MD, MSc, FACG
Discuss the treatment options beyond steroids for alcoholic hepatitis, examine whether or not alcoholics should be transplanted, and identify when to refer these patients.

HCV Treatment: Drug Therapy and Long-Term Follow-Up for HCC
Nancy S. Reau, MD, FACG
Explain treatment options for HCV and discuss whether or not HCV treatment increases the risk of HCC.

What's New in Cirrhosis Management: Medications, Treatment Complications, and Referral for Transplant
David E. Bernstein, MD, FACG
Examine portal vein thrombosis in cirrhosis patient management and assess the management of commonly prescribed and OTC medications.
LUNCHEON PRESENTATION

Burnout Among Gastroenterologists: Strategies for Practitioners at Risk!
Carol A. Burke, MD, FACP
Recognize causes of stress and burnout, and identify strategies to improve work-life balance.

SESSION 4: OBESITY
Moderator: Naga P. Chalasani, MD, FACP

Non-Surgical Management Options for Obesity
Reem Z. Sharaiha, MD, MSc
Demonstrate the new endoscopic treatments for obesity including intragastric balloons and ESG, and examine the pharmacologic options for weight loss.

Hot Topic! How to Start a Bariatrics Program in Your Practice
Shelby A. Sullivan, MD, FACP
Outline the type of endoscopic training involved, define key team members, and establish the approach to the obese patient in your practice.

Fatty Liver: Non-Invasive Assessment and Treatment Updates
Naga P. Chalasani, MD, FACP
Discuss the non-invasive assessments, treatments in the pipeline, and the risk of liver decompensation for patients with fatty liver.

AFTERNOON BREAKOUT SESSION

How I Do It: Resection of Large Colon Polyps
Douglas K. Rex, MD, MACG
Discuss the various techniques and benefits of submucosal injections, as well as techniques to minimize bleeding, perforation, and recurrence in patients with large colon polyps.

The Hot Seat: Challenging Cases of Pancreatic Cystic Neoplasms – Are the Newest Guidelines Helpful?
Case Presentation: Ajaypal Singh, MD
Panel Members: Zachary L. Smith DO, Reem Z. Sharaiha, MD, MSc, and John R. Saltzman, MD, FACP
Demonstrate the clinical approach to cystic pancreatic lesions for the general gastroenterologist, and describe the recent guidelines with regard to the role of observation, endoscopic evaluation, and surgical referral for patients with pancreatic cystic neoplasms.

Try This at Home: Difficult Common Bile Duct Stones and Options for Extraction
Ashley L. Faulx, MD, FACP
Describe the various methods of bile duct stone extraction, and evaluate the risks of large stone extraction and the management of these complications.

Sunday, August 26, 2018

SESSION 5: COLON CANCER SCREENING
Moderator: Douglas K. Rex, MD, MACG

Colon Cancer Genetic Syndromes in 2018
Carol A. Burke, MD, FACP
Summarize various polyposis syndromes and develop strategies for diagnosis and management, and referral for further genetic work-ups.

Serrated Colon Polyps: How Can We Better Identify Them?
Joshua E. Melson, MD, MPH
Distinguish the different types of serrated polyps and serrated polyposis syndrome, compare the associated risk of colon cancer development to traditional adenomas, and examine the recent guidelines on the management of serrated polyps.
Is There a Role for Chromoendoscopy and Advanced Imaging in Colonoscopy in Your Practice?
Anna M. Buchner, MD, PhD
Evaluate chromoendoscopy and advanced imaging, their roles in practice, including IBD patients, and demonstrate how to implement these techniques in routine practice.

Non-Invasive Colon Cancer Screening: Where Do We Stand in 2018?
Zachary L. Smith, DO
Describe the available and future non-invasive colon cancer screening tests, their benefits and limitations, and their appropriateness in special groups such as the elderly.

SESSION 6: GENERAL GI
Moderator: Gary W. Falk, MD, MS, FACG

PPIs: What Are the Real Risks of Long-Term Use and Should We Focus on Weaning Patients Off?
Gary W. Falk, MD, MS, FACG
Evaluate the data and their validity regarding the risks of long-term PPI therapy, and assess when providers should consider weaning patients off PPIs.

Eosinophilic Esophagitis: Medical and Endoscopic Management
Nicholas J. Shaheen, MD, MPH, FACG
Accurately diagnose EoE with an understanding of histologic findings, describe the role of medical therapies including PPIs, steroids, and immunological therapies that are being developed, and identify the indications and risks of endoscopic therapy.

Modulation of the GI Tract Bacteria: Is There Clinical Data for Probiotics and Fecal Transplant in GI Disease?
Monika Fischer, MD, MS, FACG
Distinguish the various GI diseases that may benefit from FMT, and interpret the clinical data that exists regarding the utility of probiotics in various disease states.

Surveillance and Treatment Guidelines for Barrett’s Esophagus
Prasad G. Iyer, MD, MS, FACG
Apply current guidelines for surveillance of Barrett’s esophagus, with attention to surveillance intervals, and discuss pros and cons of current treatments.

Antithrombotics and Antiplatelet Agents: Optimal Management in GI Bleeding and Endoscopy
John R. Saltzman, MD, FACG
Compare the most common antithrombotic and antiplatelet agents, and discuss if and when these agents should be held for endoscopic interventions and their management in the GI bleeding patient.
Saturday, September 8, 2018

SESSION 1: UPPER GI
Moderator: Savita Srivastava, MD

Management of Ulcer Disease in the Upper GI Tract
William D. Chey, MD, FACP
Describe management strategies currently in use and on the horizon for ulcer disease in the upper GI tract.

How I Manage Patients With Bloating
Nitin K. Ahuja, MD, MS
Recognize symptoms of upper GI functional disorders and explain how best to manage them.

Esophageal Motility Disorders: Diagnosis and Therapy
Rena H. Yadlapati, MD, MSHS
Discuss tips on interpreting motility studies of the esophagus and how to treat motility disorders.

SESSION 2: PANCREATICO-BILIARY
Moderator: Nicholas M. Intagliata, MD

How to Avoid Complications in ERCP
James M. Scheiman, MD, FACP
Identify the safest approaches to ERCP that will reduce the chance of complications.

Managing the Difficult Bile Duct Stone
Doumit S. BouHaidar, MD
Recognize what constitutes a potentially challenging bile duct stone and how best to approach it.

Diagnosing, Managing, and Following Pancreatic Cysts
Jennifer L. Maranki, MD
Explain the most current strategy to diagnose and manage pancreatic cysts.

KEYNOTE LECTURE

Quality in Gastroenterology: Where We Are in 2018
Irving M. Pike, MD, FACP
Discuss the most recent innovations and methods to ensure quality in your practice and care of your patients.

SESSION 3: LIVER
Moderator: Nicholas M. Intagliata, MD

NASH – What Therapies Are on the Horizon?
Manal F. Abdelmalek, MD, MPH, FACP
Describe recent advances in clinical trials for NASH and the promising therapies that may be on the horizon.

Treatment of Alcoholic Hepatitis: From Steroids to Liver Transplantation
Zachary H. Henry, MD
Analyze controversies in the management of alcoholic hepatitis.

A New Era in the Management of HCV Infection
Richard K. Sterling, MD, MSc, FACP
Analyze the newest approach to hepatitis C care in the United States.
SESSION 4: PRACTICE MANAGEMENT
Moderator: Savita Srivastava, MD

Incorporating Advanced Practitioners Into Your Clinical Practice
Daniel J. Pambianco, MD, FACG
Identify how advanced practitioners can play a critical role in digestive disease healthcare models in both academic and private practice settings.

New Sources of GI Revenue in the Era of Diminishing Endoscopy Reimbursement: A Primer
Jan A. Janson, MD, FACG
Summarize the vital importance of ancillary services to the profitability of private practice, specify the major opportunities in gastroenterology, and use real-life examples to demonstrate success in ancillary services.

Sunday, September 9, 2018
SESSION 5: IBD
Moderator: Savita Srivastava, MD

Managing Infections in the IBD Patient
Millie D. Long, MD, MPH, FACG
Discuss the management of IBD patients with infections, including C. difficile, pneumonia, hepatitis, mono, and post-operative infections.

Managing the Pouch Patient
Jill K. Gaidos, MD, FACG
Explain the specifics of care in pouch patients with IBD.

Therapeutic Drug Monitoring: Proactive or Reactive?
Anne G. Tuskey, MD, FACG
Summarize the current evidence for therapeutic drug monitoring in the IBD patient.

SESSION 6: LOWER GI
Moderator: Nicholas M. Intagliata, MD

Difficult Colon Polyps: Best Practice in Detection and Polypectomies in 2018
Carol A. Burke, MD, FACG
Identify the best practices for detecting and removing colon polyps, from diminutive to complex polypectomies.

Fecal Microbiota Transplantation: Practical Applications in Clinical Practice
Monika Fischer, MD, MS, FACG
Recognize the proper use of FMT in clinical practice and potential innovations in this field that are on the horizon.

Constipation – Pearls and Pitfalls
Jeanetta W. Frye, MD
Describe practical management strategies for the patient with constipation.
SESSION 1: VIRAL HEPATITIS

HCV – Treatment and Post-Treatment Follow-Up
David E. Bernstein, MD, FACG
Summarize the current management options for chronic HCV infection and describe post-treatment follow-up.

Treatment of HCV in Patients With End-Stage Organ Disease and Other Populations
Paul Y. Kwo, MD, FACG
Describe the current available treatments for patients with HCV and end-stage liver disease.

Natural History and Diagnosis of HBV
Mitchell L. Shiffman, MD, FACG
Discuss the natural history of HBV, serologies, the different immune stages of the disease, and screening recommendations for HCC in patients with HBV.

HBV Treatment
Mark W. Russo, MD, MPH, FACG
Explain current recommendations for the treatment of HBV including for pregnant patients, and strategies to prevent reactivation.

SESSION 2: DIAGNOSING AND TREATING LIVER DISEASE

Assessing Fibrosis in the Management of Chronic Liver Disease
Joseph K. Lim, MD, FACG
Discuss the strengths and weaknesses of the currently available modalities used to assess hepatic fibrosis.

Routine Care of the Patient With Cirrhosis
Catherine T. Frenette, MD
Define the liver-specific care of patients with cirrhosis including the evaluation of complications of portal hypertension.

Hepatic Encephalopathy
Mitchell L. Shiffman, MD, FACG
Identify the classification, diagnostic testing, and treatment of hepatic encephalopathy.

Hepatocellular Carcinoma
Paul Y. Kwo, MD, FACG
List risk factors, screening, evaluation methods, and treatments for patients with HCC.

The Role of the Advanced Health Care Provider in the GI Hepatology Practice
April G. Morris, FNP
Outline the role of AHCPs in working with chronic liver disease patients.

SESSION 3: CAUSES OF LIVER DISEASE

Management of NAFLD
Catherine T. Frenette, MD
Describe the causes, epidemiology, natural history, and treatment of NAFLD.

Diagnosis and Management of Alcoholic Liver Disease and Alcoholic Hepatitis
Mark W. Russo, MD, MPH, FACG
Discuss liver diseases secondary to alcohol use and their treatments.

Metabolic Liver Disorders
Joseph K. Lim, MD, FACG
Explain the causes, epidemiology, natural history, and treatments of hereditary hemochromatosis, Wilson's disease, and alpha-1 antitrypsin deficiency.
SESSION 4: PBC AND OTHER IMMUNE DISORDERS

Primary Biliary Cholangitis  
*David E. Bernstein, MD, FACG*
Identify the epidemiology, natural history, and treatments of PBC.

Autoimmune Hepatitis and Its Variants  
*Paul Y. Kwo, MD, FACG*
Explain the epidemiology, natural history, and treatments of autoimmune hepatitis and primary sclerosing cholangitis.

Drug-Induced Liver Injury  
*Mark W. Russo, MD, MPH, FACG*
Describe the typical patterns of drug-induced liver injury and commonly used medications that may cause it.
Saturday, December 1, 2018

SESSION 1: IBD
Moderator: Edward V. Loftus, Jr., MD, FACG

Update on Ulcerative Colitis
Millie D. Long, MD, MPH, FACG
Discuss care for the mild-to-moderate and the severe ulcerative colitis patient populations.

Biologic Drug Monitoring in Inflammatory Bowel Disease
David A. Schwartz, MD, FACG
Discuss how biologic drug monitoring can be utilized in patients with inflammatory bowel disease.

Positioning Biologics for Patients With Crohn's Disease in 2018
Edward V. Loftus, Jr., MD, FACG
Explain the options for new biologic therapy in patients with inflammatory bowel disease, including anti-TNF therapy, anti-integrin therapy, and IL 12-23 receptor antagonists.

Care Beyond the Gut: Health Maintenance in IBD
Sara N. Horst, MD, MPH
Describe practical health maintenance objectives for patients with inflammatory bowel disease that focus on vaccines, bone health, and psychosocial outcomes.

SESSION 2: PANCREATICOBILIARY
Moderator: Douglas G. Adler, MD, FACG

Chronic Pancreatitis Update
Timothy B. Gardner, MD, MS, FACG
List the causes of chronic pancreatitis, the most recent diagnostic strategies, and new management strategies available for these patients.

Endoscopic Management of Complex Pancreatic Fluid Collections
Patrick S. Yachimski, MD, MPH
Identify endoscopic therapy options for patients with complex pancreatic cysts.

Biliary Strictures: Why Do They Happen, and When and How Do We Treat Them Endoscopically?
Douglas G. Adler, MD, FACG
Discuss causes of biliary stricturing disease and how best to manage diagnosis and treatment endoscopically.

SESSION 3: LIVER
Moderator: Mitchell L. Shiffman, MD, FACG

Alcoholic Liver Disease Management
Nancy S. Reau, MD, FACG
Discuss new guidelines for alcoholic liver disease management.

Portal Hypertension Treatment: What Is New?
Paul Y. Kwo, MD, FACG
Discuss the current literature and new options for treating patients with esophageal and gastric varices.

Vascular Lesions and Solid Tumors of the Liver
Mitchell L. Shiffman, MD, FACG
Explain the diagnosis and management of vascular and solid lesions of the liver.

Transition of the Pediatric Liver Patient to Adult Care
Girish S. Rao, MD
Recognize the best ways to transition a pediatric liver patient to adult care.
AFTERNOON BREAKOUT SESSION

Update on SIBO
Mark Pimentel, MD, FACG
Outline the new ACG guidelines regarding the diagnosis and treatment of small bowel bacterial overgrowth.

The Future of MIPS
Caroll D. Koscheski, MD, FACG
Analyze the new landscape of the Merit-based Incentive Payment System (MIPS) and the effect it may have on gastroenterology practice in the coming years.

What Else Is Your Patient Taking? Alternative Therapies in IBD
Dawn M. Beaulieu, MD
Discuss alternative therapies including herbal supplements and dietary management for patients with inflammatory bowel disease.

Maximizing the Use of Advanced Practice Providers in the GI Practice
Timothy Denton, MD, FACG, Sara N. Horst, MD, MPH, and Julianne H. Wagnon, FNP-BC, JD
Describe how to best position advanced practice providers in a gastroenterology practice to allow for a thriving environment for all involved.

Sunday, December 2, 2018

SESSION 4: UPPER GI
Moderator: Michael F. Vaezi, MD, PhD, MSc(Epi), FACG

Esophageal Motility Disorders: Diagnosis and Management in 2018
Rena H. Yadlapati, MD, MSHS
Outline the diagnostic and treatment strategies for achalasia and other esophageal motility disorders.

Eosinophilic Esophagitis: New Options in Dietary and Medical Management
Evan S. Dellon, MD, MPH, FACG
Describe new treatment options, including dietary management, for eosinophilic esophagitis.

PPIs: What Are the Data Regarding Long-Term Use?
Colin W. Howden, MD, FACG
Understand the new data regarding side effects of proton-pump inhibitors.

Refractory GERD: What to Consider if PPIs Don't Help
Michael F. Vaezi, MD, PhD, MSc(Epi), FACG
Discuss diagnostic and treatment strategies for dyspepsia symptoms that are nonresponsive to PPIs.

SESSION 5: LOWER GI
Moderator: Timothy Denton, MD, FACG

Colorectal Cancer Screening
Robert D. Marks, MD
Assess colorectal cancer screening options.

Advanced Polypectomy Techniques
Amit Rastogi, MD
Analyze advanced polypectomy techniques for large polyps, and their potential as an alternative to major abdominal surgery.

Chronic Constipation and Pelvic Floor Dysfunction
Lin Chang, MD, FACG
Describe new therapies available for patients with chronic constipation and how pelvic floor dysfunction may play a role in certain patient populations.

FMT: How to Best Deliver Therapy
Colleen R. Kelly, MD, FACG
Discuss new modalities for delivery of FMT.